Andrew Gitkin is a managing director and head of West Coast biotechnology investment banking at Piper Jaffray. Andrew has 20 years of healthcare investment experience, most recently at Moelis & Company, where he was a senior vice president in the life sciences investment banking group. Andrew was previously with Saddle Point Asset Management and Tavistock Life Sciences. Prior to that, he was CEO of Zephyr Sciences, a biotech company engaged in the in-licensing and development of clinical stage compounds. Andrew was also a senior healthcare analyst in equity research at UBS and SalomonSmithBarney where he was awarded rankings by Institutional Investor and Greenwich Associates. Andrew holds a bachelor’s degree in business administration from the Goizueta School of Business at Emory University.